SCM
SMMT icon

Sterling Capital Management’s Summit Therapeutics SMMT Stock Holding History

Sterling Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13K Buy
891
+55
+7% +$975 ﹤0.01% 2085
2026
Q1 		$15.9K Hold
836
– – ﹤0.01% 2128
2025
Q4 		$14.6K Buy
836
+659
+372% +$12.4K ﹤0.01% 2405
2025
Q3 		$3.66K Sell
177
-2
-1% -$49 ﹤0.01% 2857
2025
Q2 		$3.81K Hold
179
– – ﹤0.01% 2658
2025
Q1 		$3.45K Sell
179
-70
-28% -$1.4K ﹤0.01% 2344
2024
Q4 		$4.44K Buy
249
+150
+152% +$2.91K ﹤0.01% 2517
2024
Q3 		$2.17K Buy
+99
New +$1.39K ﹤0.01% 2147

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Sterling Capital Management's SMMT Position: Q2 2026 in Review

Sterling Capital Management increased its Summit Therapeutics (SMMT) stake by 6.6% in Q2 2026, buying an estimated $975 and bringing the position to 891 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #2085.

Sterling Capital Management first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $15.9K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Sterling Capital Management held 891 shares of Summit Therapeutics worth $13K as of Q2 2026.
  • Sterling Capital Management bought 55 Summit Therapeutics shares in Q2 2026, an estimated $975.
  • Summit Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2085 holding.
  • Sterling Capital Management first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Summit Therapeutics position peaked at $15.9K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.